{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:55:30Z","timestamp":1740167730752,"version":"3.37.3"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Neurofibromatosis 1 and 2, although involving two different tumour suppressor genes (neurofibromin and merlin, respectively), are both cancer predisposition syndromes that disproportionately affect cells of neural crest origin. New therapeutic approaches for both NF1 and NF2 are badly needed. In promising previous work we demonstrated that two non-steroidal analogues of 2-methoxy-oestradiol (2ME2), STX3451(2-(3-bromo-4,5-dimethoxybenzyl)-7-methoxy-6-sulfamoyloxy-1,2,3,4-tetrahydroisoquinoline), and STX2895 (7-Ethyl-6-sulfamoyloxy-2-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline) reduced tumour cell growth and induced apoptosis in malignant and benign human Neurofibromatosis 1 (NF1) tumour cells. In earlier NF1 mechanism of action studies we found that in addition to their effects on non-classical hormone-sensitive pathways, STX agents acted on the actin- and myosin-cytoskeleton, as well as PI3Kinase and MTOR signaling pathways. Tumour growth in NF2 cells is affected by different inhibitors from those affecting NF1 growth pathways: specifically, NF2 cells are affected by merlin-downstream pathway inhibitors. Because Merlin, the affected tumour suppressor gene in NF2, is also known to be involved in stabilizing membrane-cytoskeletal complexes, as well as in cell proliferation, and apoptosis, we looked for potentially common mechanisms of action in the agents\u2019 effects on NF1 and NF2. We set out to determine whether STX agents could therefore also provide a prospective avenue for treatment of NF2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>STX3451 and STX2895 were tested in dose-dependent studies for their effects on growth parameters of malignant and benign NF2 human tumour cell lines in vitro. The mechanisms of action of STX3451 and STX2895 were also analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Although neither of the agents tested affected cell growth or apoptosis in the NF2 tumour cell lines tested through the same mechanisms by which they affect these parameters in NF1 tumour cell lines, both agents disrupted actin- and myosin-based cytoskeletal structures in NF2 cell lines, with subsequent effects on growth and cell death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Both STX3451 and STX2895 provide new approaches for inducing cell death and lowering tumour burden in NF2 as well as in NF1, which both have limited treatment options.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s40360-019-0369-8","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T15:03:20Z","timestamp":1573830200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nonsteroidal sulfamate derivatives as new therapeutic approaches for Neurofibromatosis 2 (NF2)"],"prefix":"10.1186","volume":"20","author":[{"given":"Yu-chi","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Arellano-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa E.","family":"Menjivar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan M.","family":"Jewett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Dohle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofiia","family":"Karchugina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Chernoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry V. L.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4851-0603","authenticated-orcid":false,"given":"Kate F.","family":"Barald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"369_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1056\/NEJM198803173181106","volume":"318","author":"RL Martuza","year":"1988","unstructured":"Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med. 1988;318:684\u20138.","journal-title":"N Engl J Med"},{"key":"369_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00401-011-0928-6","volume":"123","author":"SL Carroll","year":"2012","unstructured":"Carroll SL. Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol. 2012;123:321\u201348.","journal-title":"Acta Neuropathol"},{"key":"369_CR3","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004.","journal-title":"Nat Rev Dis Primers"},{"key":"369_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/B978-0-444-62702-5.00005-6","volume":"132","author":"DG Evans","year":"2015","unstructured":"Evans DG. Neurofibromatosis type 2. Handb Clin Neurol. 2015;132:87\u201396.","journal-title":"Handb Clin Neurol"},{"key":"369_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/GIM.0b013e3181ac9a27","volume":"11","author":"DG Evans","year":"2009","unstructured":"Evans DG. Neurofibromatosis 2 [bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med. 2009;11:599\u2013610.","journal-title":"Genet Med"},{"key":"369_CR6","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1073\/pnas.0700044104","volume":"104","author":"ME McLaughlin","year":"2007","unstructured":"McLaughlin ME, Kruger GM, Slocum KL, Crowley D, Michaud NA, Huang J, Magendantz M, Jacks T. The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. Proc Natl Acad Sci U S A. 2007;104:3261\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"369_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1101\/gad.1054603","volume":"17","author":"D Lallemand","year":"2003","unstructured":"Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 2003;17:1090\u2013100.","journal-title":"Genes Dev"},{"key":"369_CR8","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1038\/sj.onc.1202141","volume":"17","author":"PD Pelton","year":"1998","unstructured":"Pelton PD, Sherman LS, Rizvi TA, Marchionni MA, Wood P, Friedman RA, Ratner N. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene. 1998;17:2195\u2013209.","journal-title":"Oncogene"},{"key":"369_CR9","first-page":"1493","volume":"23","author":"JT Fraenzer","year":"2003","unstructured":"Fraenzer JT, Pan H, Minimo L Jr, Smith GM, Knauer D, Hung G. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol. 2003;23:1493\u2013500.","journal-title":"Int J Oncol"},{"key":"369_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ncb1339","volume":"8","author":"F Hamaratoglu","year":"2006","unstructured":"Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C, Jafar-Nejad H, Halder G. The tumour-suppressor genes NF2\/Merlin and Expanded act through hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol. 2006;8:27\u201336.","journal-title":"Nat Cell Biol"},{"key":"369_CR11","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1101\/gad.226302","volume":"16","author":"M Kalamarides","year":"2002","unstructured":"Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, Giovannini M. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 2002;16:1060\u20135.","journal-title":"Genes Dev"},{"key":"369_CR12","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1101\/gad.14.13.1617","volume":"14","author":"M Giovannini","year":"2000","unstructured":"Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A, Thomas G. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 2000;14:1617\u201330.","journal-title":"Genes Dev"},{"issue":"11","key":"369_CR13","doi-asserted-by":"publisher","first-page":"e13791","DOI":"10.1371\/journal.pone.0013791","volume":"5","author":"HY Chow","year":"2010","unstructured":"Chow HY, Stepanova D, Koch J, Chernoff J. p21-activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. PLoS One. 2010;5(11):e13791.","journal-title":"PLoS One"},{"key":"369_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ccr.2011.02.017","volume":"19","author":"C Yi","year":"2011","unstructured":"Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N, Persson NL, Shimono A, Speicher DW, Marmorstein R, et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell. 2011;19:527\u201340.","journal-title":"Cancer Cell"},{"key":"369_CR15","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.febslet.2012.03.016","volume":"586","author":"L Zhou","year":"2012","unstructured":"Zhou L, Hanemann CO. Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett. 2012;586:1403\u20138.","journal-title":"FEBS Lett"},{"key":"369_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2015.125","volume":"35","author":"AM Petrilli","year":"2016","unstructured":"Petrilli AM, Fern\u00e1ndez-Valle C. Role of Merlin\/NF2 inactivation in tumor biology. Oncogene. 2016;35:537\u201348.","journal-title":"Oncogene"},{"key":"369_CR17","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1097\/MAO.0000000000000788","volume":"36","author":"M de Vries","year":"2015","unstructured":"de Vries M, van der Mey AG, Hogendoorn PC. Tumor biology of vestibular Schwannoma: a review of experimental data on the determinants of tumor genesis and growth characteristics. Otol Neurotol. 2015;36:1128\u201336.","journal-title":"Otol Neurotol"},{"key":"369_CR18","doi-asserted-by":"crossref","unstructured":"Roger E. McLendon, Marc K. Rosenblum, Darell D. Bigner. Neurofibromatosis 2. Russell & Rubinstein\u2019s Pathology of Tumors of the Nervous System 7Ed 2006;p917\u2013927.","DOI":"10.1201\/b13439"},{"key":"369_CR19","first-page":"1","volume":"40","author":"C Matthies","year":"1997","unstructured":"Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery. 1997;40:1\u20139.","journal-title":"Neurosurgery"},{"key":"369_CR20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1054\/bjoc.1999.1030","volume":"82","author":"ME Baser","year":"2000","unstructured":"Baser ME, Evans DG, Jackler RK, Sujansky E, Rubenstein A. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer. 2000;82:998.","journal-title":"Br J Cancer"},{"key":"369_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1215\/15228517-2007-027","volume":"9","author":"A Balasubramaniam","year":"2007","unstructured":"Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, Guha A. Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro-Oncology. 2007;9:447\u201353.","journal-title":"Neuro-Oncology"},{"key":"369_CR22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","volume":"14","author":"MA Karajannis","year":"2012","unstructured":"Karajannis MA, Legault G, Hagiwara M, Ballas MS, Brown K, Nusbaum AO, Hochman T, Goldberg JD, Koch KM, Golfinos JG, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology. 2012;14:1163\u201370.","journal-title":"Neuro-Oncology"},{"key":"369_CR23","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG II, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361:358\u201367.","journal-title":"N Engl J Med"},{"key":"369_CR24","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33:1046\u201352.","journal-title":"Otol Neurotol"},{"key":"369_CR25","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, et al. Efficacy and biomarker study of Bevacizumab for hearing loss resulting from Neurofibromatosis type 2-associated vestibular Schwannomas. J Clin Oncol. 2016;34:1669\u201375.","journal-title":"J Clin Oncol"},{"key":"369_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D, Larroque B, Sterkers O, Giovannini M, Kalamarides M. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neuro-Oncol. 2015;122:313\u201320.","journal-title":"J Neuro-Oncol"},{"key":"369_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/neuonc\/nor056","volume":"13","author":"S Ammoun","year":"2011","unstructured":"Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro-Oncology. 2011;13:759\u201366.","journal-title":"Neuro-Oncology"},{"key":"369_CR28","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/neuonc\/nor072","volume":"13","author":"ML Bush","year":"2011","unstructured":"Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Yates CW, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology. 2011;13:983\u201399.","journal-title":"Neuro-Oncology"},{"issue":"15_suppl","key":"369_CR29","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1200\/JCO.2016.34.15_suppl.2558","volume":"34","author":"Hugo Valencia","year":"2016","unstructured":"Valencia H, Newton HB, Hade E, Sborov DW, Cavaliere R, Poi M, Phelps M, Wang J, Coss CC, Khountham S, et al. A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors. J Clin Oncol 2016;34: suppl; abstr 2558.","journal-title":"Journal of Clinical Oncology"},{"key":"369_CR30","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/bjc.2015.345","volume":"113","author":"YC Shen","year":"2015","unstructured":"Shen YC, Upadhyayula R, Cevallos S, Messick RJ, Hsia T, Leese MP, Jewett DM, Ferrer-Torres D, Roth TM, Dohle W, Potter BVL, Barald KF. Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol. Br J Cancer. 2015;113:1158\u201367.","journal-title":"Br J Cancer"},{"key":"369_CR31","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/cmdc.201300412","volume":"9","author":"W Dohle","year":"2014","unstructured":"Dohle W, Leese MP, Jourdan FL, Chapman CJ, Hamel E, Ferrandis E, Potter BVL. Optimisation of tetrahydroisoquinoline-based chimeric microtubule disruptors. ChemMedChem. 2014;9:1783\u201393.","journal-title":"ChemMedChem"},{"key":"369_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/cmdc.201300261","volume":"9","author":"MP Leese","year":"2014","unstructured":"Leese MP, Jourdan FL, Major MR, Dohle W, Hamel E, Ferrandis E, Fiore A, Kasprzyk PG, Potter BVL. Tetrahydroisoquinolinone-based steroidomimetic and chimeric microtubule disruptors. ChemMedChem. 2014;9:85\u2013108.","journal-title":"ChemMedChem"},{"key":"369_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jsbmb.2015.03.012","volume":"153","author":"MP Thomas","year":"2015","unstructured":"Thomas MP, Potter BVL. Estrogen O-sulfamates and their analogues: clinical steroid sulfatase inhibitors with broad potential. J Steroid Biochem Mol Biol. 2015;153:160\u20139.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"369_CR34","doi-asserted-by":"publisher","first-page":"7634","DOI":"10.1021\/acs.jmedchem.5b00386","volume":"58","author":"MP Thomas","year":"2015","unstructured":"Thomas MP, Potter BVL. Discovery and development of the aryl O-Sulfamate moiety for oncology and women\u2019s health. J Med Chem. 2015;58:7634\u201358.","journal-title":"J Med Chem"},{"key":"369_CR35","doi-asserted-by":"publisher","first-page":"T233","DOI":"10.1530\/JME-18-0045","volume":"61","author":"BVL Potter","year":"2018","unstructured":"Potter BVL. SULFATION PATHWAYS: steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects. J Mol Endocrinol. 2018;61:T233\u201352.","journal-title":"J Mol Endocrinol"},{"key":"369_CR36","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/sj.bjc.6601591","volume":"90","author":"CR Ireson","year":"2004","unstructured":"Ireson CR, Chander SK, Purohit A, Parish DC, Woo LW, Potter BVL, Reed MJ. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer. 2004;90:932\u20137.","journal-title":"Br J Cancer"},{"key":"369_CR37","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1021\/acs.jmedchem.8b01990","volume":"62","author":"JT Andring","year":"2019","unstructured":"Andring JT, Dohle W, Tu C, Potter BVL, McKenna R. STX140 and non-steroidal Sulfamate derivatives inhibit a carbonic anhydrase IX: structure-activity optimization for isoform selectivity. J Med Chem. 2019;62:2202\u201312.","journal-title":"J Med Chem"},{"key":"369_CR38","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.2147\/DDDT.S152718","volume":"12","author":"M Nel","year":"2018","unstructured":"Nel M, Joubert AM, Dohle W, Potter BVL, Theron AE. Modes of cell death induced by tetrahydroisoquinoline-based analogs in MDA-MB-231 breast and A549 lung cancer cell lines. Drug Design, Development and Therapy. 2018;12:1881\u2013904.","journal-title":"Drug Design, Development and Therapy"},{"key":"369_CR39","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/1097-0142(19891201)64:11<2243::AID-CNCR2820641110>3.0.CO;2-S","volume":"64","author":"K Tanaka","year":"1989","unstructured":"Tanaka K, Sato C, Maeda Y, Koike M, Matsutani M, Yamada K, Miyaki M. Establishment of a human malignant meningioma cell line with amplified c-myc oncogene. Cancer. 1989;64:2243\u20139.","journal-title":"Cancer"},{"key":"369_CR40","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/labinvest.3700307","volume":"85","author":"S P\u00fcttmann","year":"2005","unstructured":"P\u00fcttmann S, Senner V, Braune S, Hillmann B, Exeler R, Rickert CH, Paulus W. Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Investig. 2005;85:1163\u201371.","journal-title":"Lab Investig"},{"key":"369_CR41","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.18632\/oncotarget.2810","volume":"6","author":"HY Chow","year":"2015","unstructured":"Chow HY, Dong B, Duron SG, Campbell DA, Ong CC, Hoeflich KP, Chang LS, Welling DB, Yang ZJ, Chernoff J. Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget. 2015;6:1981\u201394.","journal-title":"Oncotarget"},{"key":"369_CR42","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3171\/jns.1995.82.5.0864","volume":"82","author":"JC Tsai","year":"1995","unstructured":"Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg. 1995;82:864\u201373.","journal-title":"J Neurosurg"},{"key":"369_CR43","first-page":"475","volume":"20","author":"G Hung","year":"2002","unstructured":"Hung G, Li X, Faudoa R, Xeu Z, Kluwe L, Rhim JS, Slattery W, Lim D. Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol. 2002;20:475\u201382.","journal-title":"Int J Oncol"},{"key":"369_CR44","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1227\/00006123-199009000-00008","volume":"27","author":"WH Lee","year":"1990","unstructured":"Lee WH. Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery. 1990;27:389\u201395.","journal-title":"Neurosurgery"},{"key":"369_CR45","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1039\/c002558e","volume":"46","author":"MP Leese","year":"2010","unstructured":"Leese MP, Jourdan F, Kimberley MR, Cozier GE, Thiyagarajan N, Stengel C, Regis-Lydi S, Foster PA, Newman SP, Acharya K, et al. Chimeric microtubule disruptors. Chem Commun. 2010;46:2907\u20139.","journal-title":"Chem Commun"},{"key":"369_CR46","doi-asserted-by":"publisher","first-page":"9446","DOI":"10.1073\/pnas.0911863107","volume":"107","author":"BW Murray","year":"2010","unstructured":"Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010;107:9446\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"369_CR47","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/glia.20534","volume":"55","author":"TM Roth","year":"2007","unstructured":"Roth TM, Ramamurthy P, Ebisu F, Lisak RP, Bealmear BM, Barald KF. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation. Glia. 2007;55:1123\u201333.","journal-title":"Glia"},{"key":"369_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/dvdy.21430","volume":"237","author":"TM Roth","year":"2008","unstructured":"Roth TM, Ramamurthy P, Muir D, Wallace M, Zhu Y, Chang L, Barald KF. Influence of hormones and hormone metabolites on the growth of Schwann cells derived from embryonic stem cells and on tumor cell lines expressing variable levels of neurofibromin. Dev Dyn. 2008;237:513\u201324.","journal-title":"Dev Dyn"},{"key":"369_CR49","doi-asserted-by":"publisher","first-page":"10252","DOI":"10.1158\/0008-5472.CAN-07-0618","volume":"67","author":"M Iwasaki","year":"2007","unstructured":"Iwasaki M, Homma S, Hishiya A, Dolezal SJ, Reed JC, Takayama S. BAG3 regulates motility and adhesion of epithelial cancer cells. Cancer Res. 2007;67:10252\u20139.","journal-title":"Cancer Res"},{"key":"369_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1083\/jcb.201404067","volume":"207","author":"KT Chan","year":"2014","unstructured":"Chan KT, Asokan SB, King SJ, Bo T, Dubose ES, Liu W, Berginski ME, Simon JM, Davis IJ, Gomez SM, et al. LKB1 loss in melanoma disrupts directional migration toward extracellular matrix cues. J Cell Biol. 2014;207:299\u2013315.","journal-title":"J Cell Biol"},{"issue":"5","key":"369_CR51","doi-asserted-by":"publisher","first-page":"e0126846","DOI":"10.1371\/journal.pone.0126846","volume":"10","author":"A Crabb\u00e9","year":"2015","unstructured":"Crabb\u00e9 A, Liu Y, Sarker SF, Bonenfant NR, Barrila J, Borg ZD, Lee JJ, Weiss DJ, Nickerson CA. Recellularization of decellularized lung scaffolds is enhanced by dynamic suspension culture. PLoS One. 2015;10(5):e0126846.","journal-title":"PLoS One"},{"key":"369_CR52","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/10409230903193307","volume":"44","author":"B Fadeel","year":"2009","unstructured":"Fadeel B, Xue D. The ins and outs of phospholipid asymmetry in the plasma membrane: roles in health and disease. Crit Rev Biochem Mol Biol. 2009;44:264\u201377.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"369_CR53","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1146\/annurev-cellbio-101011-155711","volume":"29","author":"S Etienne-Manneville","year":"2013","unstructured":"Etienne-Manneville S. Microtubules in cell migration. Annu Rev Cell Dev Biol. 2013;29:471\u201399.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"369_CR54","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1021\/acs.jmedchem.7b01474","volume":"61","author":"W Dohle","year":"2018","unstructured":"Dohle W, Jourdan FL, Menchon G, Prota AE, Foster PA, Mannion P, Hamel E, Thomas MP, Kasprzyk PG, Ferrandis E, et al. Quinazolinone-based anticancer agents: synthesis, Antiproliferative SAR, Antitubulin activity, and tubulin co-crystal structure. J Med Chem. 2018;61:1031\u201344.","journal-title":"J Med Chem"},{"key":"369_CR55","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1021\/acsomega.8b02879","volume":"4","author":"W Dohle","year":"2019","unstructured":"Dohle W, Prota AE, Menchon G, Hamel E, Steinmetz MO, Potter BVL. Tetrahydroisoquinoline Sulfamates as potent microtubule disruptors: synthesis, anti-proliferative and anti-tubulin activity of Dichlorobenzyl derivatives and a tubulin co-crystal structure. ACS Omega. 2019;4:755\u201364.","journal-title":"ACS Omega"},{"key":"369_CR56","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1097\/MLG.0b013e318177e20b","volume":"118","author":"AK Patel","year":"2008","unstructured":"Patel AK, Alexander TH, Andalibi A, Ryan AF, Doherty JK. Vestibular Schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors. Laryngoscope. 2008;118:1458\u201363.","journal-title":"Laryngoscope"},{"key":"369_CR57","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1227\/01.NEU.0000255421.78431.AE","volume":"60","author":"M Simon","year":"2007","unstructured":"Simon M, Bostr\u00f6m JP, Hartmann C. Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery. 2007;60:787\u201398.","journal-title":"Neurosurgery"},{"key":"369_CR58","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00006123-199308000-00005","volume":"33","author":"A Brandis","year":"1993","unstructured":"Brandis A, Mirzai S, Tatagiba M, Walter GF, Samii M, Ostertag H. Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features. Neurosurgery. 1993;33:212\u20137.","journal-title":"Neurosurgery"},{"key":"369_CR59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3171\/jns.2006.105.2.163","volume":"105","author":"S Pravdenkova","year":"2006","unstructured":"Pravdenkova S, Al-Mefty O, Sawyer J, Husain M. Progesterone and estrogen receptors: opposing prognostic indicators in meningioma. J Neurosurg. 2006;105:163\u201373.","journal-title":"J Neurosurg"},{"key":"369_CR60","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3171\/jns.2003.99.5.0848","volume":"99","author":"BS Jhawar","year":"2003","unstructured":"Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ. Sex steroid hormone exposures and risk for meningioma. J Neurosurg. 2003;99:848\u201353.","journal-title":"J Neurosurg"},{"key":"369_CR61","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/aje\/kwj254","volume":"164","author":"A Wigertz","year":"2006","unstructured":"Wigertz A, L\u00f6nn S, Mathiesen T, Ahlbom A, Hall P, Feychting M, Swedish Interphone Study Group. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol. 2006;164:629\u201336.","journal-title":"Am J Epidemiol"},{"key":"369_CR62","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3171\/2009.8.JNS09201","volume":"112","author":"S Vadivelu","year":"2010","unstructured":"Vadivelu S, Sharer L, Schulder M. Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. J Neurosurg. 2010;112:920\u20134.","journal-title":"J Neurosurg"},{"key":"369_CR63","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/07357900601062339","volume":"24","author":"SM Grunberg","year":"2006","unstructured":"Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Investig. 2006;24:727\u201333.","journal-title":"Cancer Investig"},{"key":"369_CR64","doi-asserted-by":"publisher","first-page":"67","DOI":"10.18632\/oncotarget.1557","volume":"5","author":"RD Schroeder","year":"2014","unstructured":"Schroeder RD, Angelo LS, Kurzrock R. NF2\/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget. 2014;5:67\u201377.","journal-title":"Oncotarget"},{"key":"369_CR65","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/neuonc\/not150","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis MA, Legault G, Hagiwara M, Giancotti FG, Filatov A, Derman A, Hochman T, Goldberg JD, Vega E, Wisoff JH, et al. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology. 2014;16:292\u20137.","journal-title":"Neuro-Oncology"},{"key":"369_CR66","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/bjc.2014.188","volume":"111","author":"C Stengel","year":"2014","unstructured":"Stengel C, Newman SP, Day JM, Chander SK, Jourdan FL, Leese MP, Ferrandis E, Regis-Lydi S, Potter BVL, Reed MJ, Purohit A, Foster PA. In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer. Br J Cancer. 2014;111:300\u20138.","journal-title":"Br J Cancer"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-019-0369-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-019-0369-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-019-0369-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T16:17:42Z","timestamp":1664986662000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-019-0369-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["369"],"URL":"https:\/\/doi.org\/10.1186\/s40360-019-0369-8","relation":{},"ISSN":["2050-6511"],"issn-type":[{"type":"electronic","value":"2050-6511"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"16 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}